What is INMB's current stock price?

INMB (INmune Bio, Inc.) is currently trading at $1.45 with a market cap of $38.5M.

What sector is INmune Bio, Inc. in?

INmune Bio, Inc. (INMB) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is INMB a good stock to buy?

Analysts have a Buy consensus on INMB with a price target of $22.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

INMB INmune Bio, Inc.

Healthcare

$1.45+0.69%ClosedMarket Cap: $38.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.96

P/S

0.00

EV/EBITDA

-0.70

DCF Value

$0.76

FCF Yield

-53.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-170.9%

ROA

-161.1%

ROIC

-204.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-5.4M	$—
Q4 null	$0.00	$-5.3M	$—
FY null	$50.0K	$-45.9M	$—
Q3 null	$0.00	$-6.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$22.00

Target (Median)

$22.00

Target Range

$22.00 - $22.00

1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

LUCID CAPITAL MARKETSBuy

2026-03-11

Maxim GroupBuy

2025-07-02

BTIGNeutral

2025-07-01

ScotiabankSector Underperform

2025-07-01

Trading Activity

Insider Trades

View All

Schroeder Timothy jdirector

SellTue Dec 02

Moss David Jdirector, officer: Chief Executive Officer

SellTue Dec 02

Lowdell Mark Williamofficer: Chief Scientific Officer

SellTue Dec 02

Juda Scottdirector

SellTue Dec 02

Ganjei James Kellydirector

SellTue Dec 02

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.05

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Peers

CVM